



Second Quarter 2022 Results

Delivering on our purpose of using the power of leading-edge science to save and improve lives around the world



Achieved important regulatory approvals and clinical advancements across research pipeline



Broad and growing late-stage cardiovascular pipeline and portfolio



Continued to deliver commercial success across broad set of growth drivers, including KEYTRUDA, GARDASIL, GARDASIL 9 and Animal Health



Strong Q2 performance reflects continued business momentum

Updated 2022 financial outlook underscores ongoing success

	Worldwide Sales	GAAP EPS	Non-GAAP EPS
Strong Q2 performance reflects continued business momentum	\$14.6B	\$1.55	\$1.87
Updated 2022 financial outlook underscores ongoing success	\$57.5B to \$58.5B	\$5.89 to \$5.99	\$7.25 to \$7.35

Sales

KEYTRUDA[®]
(pembrolizumab) Injection 100 mg

Grew ▲ to
26% **\$5.3B**

GARDASIL[®]
(Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant)

Grew ▲ to
36% **\$1.7B**

Lagevrio^{*}
molnupiravir

\$1.2B

MSD
Animal Health

\$1.5B



“I continue to be immensely proud of how the MSD team is performing in all facets of our business – scientifically, commercially and operationally.

Our strategy is working and our future is bright. I am very confident that we are well-positioned to achieve our near- and long-term goals, anchored by our commitment to deliver innovative medicines and vaccines to patients and value to all of our stakeholders, including shareholders.”

Rob Davis
Chief Executive Officer and President, MSD

*LAGEVRIO is not approved, but is authorized for emergency use by the FDA.